欧盟GMP附录15：确认与验证(修订版英文+中文)

EUROPEAN COMMISSION

ENTERPRISE DIRECTORATE-GENERAL

Single market, regulatory environment, industries under vertical legislation

Pharmaceuticals and cosmetics

Brussels,30 March 2015

EudraLex

欧盟药品管理法 Volume 4 EU Guidelines for

Good Manufacturing Practice for

Medicinal Products for Human and Veterinary Use

第四卷 欧盟人用和兽用药品GMP指南 Annex 15: Qualification and Validation 附录15:确认和验证 Legal basis for publishing the detailed guidelines:Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.

发布该细化指南的法律依据:人用药物欧共体法案指令2001/83/EC第47章和兽用药物欧共体法案指令2001/82/EC第51章。本文件为人药GMP指令2003/94/EC以及兽药GMP

指令91/412/EEC的原则和指南提供诠释。

Status of the document: Revision

文件状态：修订版

Reasons for changes: Since Annex 15 was published in 2001 the manufacturing and regulatory environment has changed significantly and an update is required to this Annex to reflect this changed environment. This revision to Annex 15 takes into account changes to other sections of the EudraLex, Volume 4, Part I, relationship to Part II, Annex 11, ICH Q8, Q9, Q10 and Q11, QWP guidance on process validation, and changes in manufacturing technology.

变更原因：从2001年附录15发布以后，制药生产和法规环境都有了显著变化，需要相应的更新来反映变化的环境。本文对附录15所做的修订考虑了欧盟法规第四卷第一部分质量管理和第二部分活性物质作起始物料以及附录11计算机化系统的验证、ICH Q8药物研发、ICH Q9质量风向管理、ICH Q11药物研发和生产、质量工作组的工艺验证指南和生产技术的变化。

Deadline for coming into operation:1 October 2015

最终实施日期：2015年10月1日

第 1 页 共36 页

第 1 页 共36 页